Post-ischemic treatment with L-kynurenine sulfate exacerbates neuronal damage after transient middle cerebral artery occlusion

Neuroscience

Volumn 247, Issue , 2013, Pages 95-101

  Gellert L ^a   Knapp, L ^a   Nemeth K ^b   Heredi J ^a   Varga, D ^a   Olah G ^a   Kocsis, K ^a   Menyhárt, Á ^a   Kis, Z ^a   Farkas, T ^a   Vecsei L ^a   Toldi, J ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

Focal cerebral ischemia; Glycine co agonist site; Kynurenines; MCAO model; Neuroprotection; NMDAR

Indexed keywords

KYNURENINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; HISTOPATHOLOGY; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT; SOMATOSENSORY CORTEX;

3-HK; 3-HYDROXYKYNURENINE; CENTRAL NERVOUS SYSTEM; CNS; DISTAL MIDDLE CEREBRAL ARTERY; DISTAL MIDDLE CEREBRAL ARTERY OCCLUSION; DMCA; DMCAO; EEG; ELECTROENCEPHALOGRAPHY; FOCAL CEREBRAL ISCHEMIA; GLYCINE CO-AGONIST SITE; I/H; ISCHEMIC/HYPOXIC; KYNA; KYNURENIC ACID; KYNURENINES; L-KYNS; L-KYNURENINE SULFATE; MCAO MODEL; N-METHYL-D-ASPARTATE; N-METHYL-D-ASPARTATE RECEPTORS; NDS; NEUROPROTECTION; NMDA; NMDAR; NORMAL DONKEY SERUM; PB; PHOSPHATE BUFFER; QUIN; QUINOLINIC ACID;

ANIMALS; INFARCTION, MIDDLE CEREBRAL ARTERY; KYNURENINE; MALE; NEURONS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84879458180     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.04.063     Document Type: Article

References (48)

1. Aspey B.S., Taylor F.L., Terruli M., Harrison M.J. Temporary middle cerebral artery occlusion in the rat: consistent protocol for a model of stroke and reperfusion. Neuropathol Appl Neurobiol 2000, 26:232-242.
2. Banerjee J., Alkondon M., Pereira E.F., Albuquerque E.X. Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. J Pharmacol Exp Ther 2012, 341:500-509.
3. Benveniste H., Drejer J., Schousboe A., Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984, 43:1369-1374.
4. Chauvel V., Vamos E., Pardutz A., Vecsei L., Schoenen J., Multon S. Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp Neurol 2012, 236:207-214.
5. Chen H.S., Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006, 97:1611-1626.
6. Delorme A., Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods 2004, 134:9-21.
7. Endres M., Dirnagl U. Ischemia and stroke. Adv Exp Med Biol 2002, 513:455-473.
8. Fuchs S.A., Peeters-Scholte C.M., de Barse M.M., Roeleveld M.W., Klomp L.W., Berger R., de Koning T.J. Increased concentrations of both NMDA receptor co-agonists d-serine and glycine in global ischemia: a potential novel treatment target for perinatal asphyxia. Amino Acids 2012, 43:355-363.
9. Gellert L., Fuzik J., Goblos A., Sarkozi K., Marosi M., Kis Z., Farkas T., Szatmari I., Fulop F., Vecsei L., Toldi J. Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur J Pharmacol 2011, 667:182-187.
10. Gigler G., Szenasi G., Simo A., Levay G., Harsing L.G., Sas K., Vecsei L., Toldi J. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol 2007, 564:116-122.
11. Guillemin G.J., Kerr S.J., Smythe G.A., Smith D.G., Kapoor V., Armati P.J., Croitoru J., Brew B.J. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001, 78:842-853.
12. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 2009, 60:279-286.
13. Hardingham G.E. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 2009, 37:1147-1160.
14. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010, 11:682-696.
15. Hetman M., Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem 2006, 6:787-799.
16. Heyes M.P., Nowak T.S. Delayed increases in regional brain quinolinic acid follow transient ischemia in the gerbil. J. Cerebral Blood Flow Metab. 1990, 10:660-667.
17. Ikonomidou C., Stefovska V., Turski L. Neuronal death enhanced by N-methyl-d-aspartate antagonists. Proc Natl Acad Sci U S A 2000, 97:12885-12890.
18. Ikonomidou C., Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol 2002, 1:383-386.
19. Kussius C.L., Popescu G.K. Kinetic basis of partial agonism at NMDA receptors. Nat Neurosci 2009, 12:1114-1120.
20. Li S.T., Ju J.G. Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities. Curr Drug Targets 2012, 13:207-221.
21. Li Y., Krupa B., Kang J.S., Bolshakov V.Y., Liu G. Glycine site of NMDA receptor serves as a spatiotemporal detector of synaptic activity patterns. J Neurophysiol 2009, 102:578-589.
22. Lugo-Huitron R., Blanco-Ayala T., Ugalde-Muniz P., Carrillo-Mora P., Pedraza-Chaverri J., Silva-Adaya D., Maldonado P.D., Torres I., Pinzon E., Ortiz-Islas E., Lopez T., Garcia E., Pineda B., Torres-Ramos M., Santamaria A., La Cruz V.P. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 2011, 33:538-547.
23. Memezawa H., Smith M.L., Siesjo B.K. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke 1992, 23:552-559.
24. Moroni F., Cozzi A., Sili M., Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm 2012, 119:133-139.
25. Moskowitz M.A., Lo E.H., Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010, 67:181-198.
26. Muir K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006, 6:53-60.
27. Nakazawa K., McHugh T.J., Wilson M.A., Tonegawa S. NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci 2004, 5:361-372.
28. Papadia S., Soriano F.X., Leveille F., Martel M.A., Dakin K.A., Hansen H.H., Kaindl A., Sifringer M., Fowler J., Stefovska V., McKenzie G., Craigon M., Corriveau R., Ghazal P., Horsburgh K., Yankner B.A., Wyllie D.J., Ikonomidou C., Hardingham G.E. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 2008, 11:476-487.
29. Papouin T., Ladepeche L., Ruel J., Sacchi S., Labasque M., Hanini M., Groc L., Pollegioni L., Mothet J.P., Oliet S.H. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150:633-646.
30. Paxinos G., Watson C.R., Emson P.C. AChE-stained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 1980, 3:129-149.
31. Petralia R.S., Wang Y.X., Hua F., Yi Z., Zhou A., Ge L., Stephenson F.A., Wenthold R.J. Organization of NMDA receptors at extrasynaptic locations. Neuroscience 2010, 167:68-87.
32. Pohl D., Bittigau P., Ishimaru M.J., Stadthaus D., Hubner C., Olney J.W., Turski L., Ikonomidou C. N-Methyl-d-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci U S A 1999, 96:2508-2513.
33. Popp A., Jaenisch N., Witte O.W., Frahm C. Identification of ischemic regions in a rat model of stroke. PLoS ONE 2009, 4:e4764.
34. Sas K., Csete K., Vecsei L., Papp J.G. Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits. J Cardiovasc Pharmacol 2003, 42:403-409.
35. Sas K., Robotka H., Rozsa E., Agoston M., Szenasi G., Gigler G., Marosi M., Kis Z., Farkas T., Vecsei L., Toldi J. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol Dis 2008, 32:302-308.
36. Schmued L.C., Stowers C.C., Scallet A.C., Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 2005, 1035:24-31.
37. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002, 303:1-10.
38. Shepard P.D., Joy B., Clerkin L., Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003, 28:1454-1462.
39. Stanika R.I., Villanueva I., Kazanina G., Andrews S.B., Pivovarova N.B. Comparative impact of voltage-gated calcium channels and NMDA receptors on mitochondria-mediated neuronal injury. J Neurosci 2012, 32:6642-6650.
40. Stone T.W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 2000, 21:149-154.
41. Stone T.W., Addae J.I. The pharmacological manipulation of glutamate receptors and neuroprotection. Eur J Pharmacol 2002, 447:285-296.
42. Swartz K.J., During M.J., Freese A., Beal M.F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990, 10:2965-2973.
43. Vamos E., Pardutz A., Klivenyi P., Toldi J., Vecsei L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci 2009, 283:21-27.
44. Vecsei L., Szalardy L., Fulop F., Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013, 12:64-82.
45. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull 2010, 36:211-218.
46. Wu H.Q., Guidetti P., Goodman J.H., Varasi M., Ceresoli-Borroni G., Speciale C., Scharfman H.E., Schwarcz R. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience 2000, 97:243-251.
47. Zadori D., Klivenyi P., Vamos E., Fulop F., Toldi J., Vecsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 2009, 116:1403-1409.
48. Zhang S.J., Steijaert M.N., Lau D., Schutz G., Delucinge-Vivier C., Descombes P., Bading H. Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 2007, 53:549-562.